UCLA researchers use F-18 FDDNP to visualize beta-amyloid load in vivo
CONTEXT: Neurotoxic beta-amyloid accumulates in regions of the brain affected by advanced Alzheimer's disease. It is a suspected contributor to the development of the condition.
RESULTS: Dr. Jorge Barrio and researchers from the University of California, Los Angeles demonstrated that F-18 FDDNP microPET can visualize b-amyloid load in vivo in the brains of transgenic mice. Dynamic scans with the agent were performed on three experimental and two control animals. FDDNP uptake was elevated in the cerebral cortex, most prominently in the frontal lobe and hippocampal regions of the experimental transgenic mice (p = 0.001). Only background cortical binding was seen in control subjects. Results were consistent with previous in vitro results with b-amyloid neurofibrils and brain specimens of Alzheimer's disease patients. They were presented at the 2005 Academy of Molecular Imaging meeting.
IMPLICATIONS: The ability to quantify beta-amyloid plaque load could identify healthy adults who are suspicious for the future development of AD and could play a role in monitoring the effect of anti-amyloid therapies.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
